Does Rallies show Form 4 insider transactions for LXRX?

Yes. Rallies tracks LXRX insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.

Is LXRX research on Rallies investment advice?

No. Rallies provides research, data, and educational context for LXRX. It does not provide personalized investment advice.

LXRX (Lexicon Pharmaceuticals, Inc.) Stock Analysis - Insider Trades

Lexicon Pharmaceuticals, Inc. (LXRX) is a publicly traded Healthcare sector company. As of May 21, 2026, LXRX trades at $2.23 with a market cap of $950.58M and a P/E ratio of -31.07. LXRX moved +4.23% today. Year to date, LXRX is +93.86%; over the trailing twelve months it is +287.72%. Its 52-week range spans $0.28 to $2.53. Analyst consensus is strong buy with an average price target of $4.03. Rallies surfaces LXRX's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who is trading LXRX stock inside the company?

Recent LXRX insider activity includes DEBBANE RAYMOND bought 2.00K, DEBBANE RAYMOND bought 100.00K, DEBBANE RAYMOND bought 100.00K, DEBBANE RAYMOND bought 50.00K, and DEBBANE RAYMOND bought 133.69K. Rallies tracks insider transaction dates, shares, prices, and estimated values.

LXRX Key Metrics

Key financial metrics for LXRX
Metric	Value
Price	$2.23
Market Cap	$950.58M
P/E Ratio	-31.07
EPS	$-0.07
Dividend Yield	0.00%
52-Week High	$2.53
52-Week Low	$0.28
Volume	0
Avg Volume	0
Revenue (TTM)	$69.64M
Net Income	$-26.09M
Gross Margin	99.50%

Recent LXRX Insider Trades

DEBBANE RAYMOND bought 2.00K (~$2.98K) on Feb 25, 2026.
DEBBANE RAYMOND bought 100.00K (~$147.00K) on Feb 23, 2026.
DEBBANE RAYMOND bought 100.00K (~$147.79K) on Feb 20, 2026.
DEBBANE RAYMOND bought 50.00K (~$71.97K) on Feb 19, 2026.
DEBBANE RAYMOND bought 133.69K (~$176.47K) on Feb 18, 2026.

Latest LXRX News

Lexicon Pharmaceuticals Delivers $0.00 Q1 EPS, Beats $0.04 Loss Estimate — May 7, 2026
Lexicon’s PROGRESS Data Shows Pilavapadin 10 mg Reduces Pain at Week 8, Supports Phase 3 — Apr 17, 2026
Lexicon to Present SCORED Analysis with BMI-Independent Heart Failure, MACE Reductions and HFpEF Quality-of-Life Data — Mar 24, 2026
Lexicon Earns $10 Million Milestone as Novo Nordisk Launches LX9851 Phase 1 Trial — Mar 23, 2026
Lexicon Shows Sotagliflozin Cuts HbA1c, Weight and Hypoglycemia Events in CKD Subgroups — Mar 11, 2026

LXRX Analyst Consensus

4 analysts cover LXRX: 0 strong buy, 3 buy, 1 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $4.03.

Common questions about LXRX

Who is trading LXRX stock inside the company?: Recent LXRX insider activity includes DEBBANE RAYMOND bought 2.00K, DEBBANE RAYMOND bought 100.00K, DEBBANE RAYMOND bought 100.00K, DEBBANE RAYMOND bought 50.00K, and DEBBANE RAYMOND bought 133.69K. Rallies tracks insider transaction dates, shares, prices, and estimated values.
Does Rallies show Form 4 insider transactions for LXRX?: Yes. Rallies tracks LXRX insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.
Is LXRX research on Rallies investment advice?: No. Rallies provides research, data, and educational context for LXRX. It does not provide personalized investment advice.